Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353234 | 1.00 | ALDH1A1 (0.40) | ALDH1A1TDP1TSHRPRSS1PRSS2 | |
| SCHEMBL8921670 | 0.78 | CYP3A4 (0.46) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12887727 | 0.78 | CD44 (0.34) | TSHRPOLBSMN1; SMN2 | |
| SCHEMBL12038096 | 0.78 | — | — | |
| SCHEMBL10053219 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL29951899 | 0.78 | HDAC1 (0.37) | TSHRACHEHTT | |
| SCHEMBL29954363 | 0.78 | CYP3A4 (0.46) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL1642304 | 0.78 | ACHE (0.37) | TSHRACHESMN1; SMN2 | |
| SCHEMBL9289476 | 0.78 | CYP3A4 (0.50) | ALDH1A1TDP1TSHRDHFRSMN1; SMN2 | |
| SCHEMBL12383641 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHRHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242562-A1 | Compound of Formula (I), a Semiconductor Material Comprising at Least One Compound of Formula (I), a Semiconductor Layer Comprising at Least One Compound of Formula (I) and an Electronic Device Comprising at Least One Compound of Formula (I) | NOVALED GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9643952-B2 | Pyridone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-17 | — | — | US | disclosed |
| US-9181280-B2 | Factor VIIa inhibitor | PHARMACYCLICS LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150315172-A1 | PYRIDONE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-9162986-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-8975405-B2 | Indenopyridine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-10 | — | — | US | disclosed |
| US-7759390-B2 | chemokine receptor 9(CCR9) antagonists such as, 5-Chloro-thiophene-2-sulfonic acid (4-cyano-2-methyl-phenyl)-amide, used for treating autimmune and inflammatory diseases, transplantat rejection and cancer | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20100060834-A1 | COPOLYIMIDE, LIQUID CRYSTAL ALIGNING LAYER COMPRISING THE SAME , AND LIQUID CRYSTAL DISPLAY COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2010-03-11 | — | — | US | disclosed |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYLICS, INC. A DELAWARE CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| US-7479502-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | disclosed |
| US-7449493-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275250-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1697296-A2 | COPPER (I) FORMATE COMPLEXES | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058789-A2 | COPPER (I) FORMATE COMPLEXES | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | ALDH1A1 2322/4885TDP1 4702/4885TSHR 816/4885 |
| US-20080300295-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | ALDH1A1 1383/4885TDP1 1280/4885TSHR 1137/4885 |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | ALDH1A1 4554/4885TDP1 956/4885TSHR 2948/4885 |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | ALDH1A1 1165/4885TDP1 2269/4885TSHR 3036/4885 |
| US-20150315172-A1 | PYRIDONE COMPOUND | HRH4, HRH3, HRH1 | ALDH1A1 443/4885TDP1 2026/4885TSHR 1516/4885 |
| US-20230242562-A1 | Compound of Formula (I), a Semiconductor Material Comprising at Least One Compound of Formula (I), a Semiconductor Layer Comprising at Least One Compound of Formula (I) and an Electronic Device Comprising at Least One Compound of Formula (I) | AFF4, AFF1, AFF2 | ALDH1A1 722/4885TDP1 4680/4885TSHR 2675/4885 |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | F13B, HABP2, F7 | ALDH1A1 2997/4885TDP1 2108/4885TSHR 2584/4885 |
| US-20080275250-A1 | Factor Viia Inhibitor | F7, F9, F5 | ALDH1A1 3376/4885TDP1 1967/4885TSHR 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.